ライフサイエンスコーパス: plasmin inhibitor

1 Plasmin activity was blocked using alpha(2)-plasmin inhibitor.

2 n S activity, protein C antigen, and alpha-2 plasmin inhibitor.

3 X, XI, XII, protein S activity, and alpha-2 plasmin inhibitor.

4 plasmin(ogen) and is only a kinetically slow plasmin inhibitor.

5 up is a beneficial element for the design of plasmin inhibitors.

6 lycan mimetics (NSGMs), as direct allosteric plasmin inhibitors.

7 Preincubation with a plasmin inhibitor, a PAR-1 antagonist, or a protein kina

8 Covalent incorporation (cross-linking) of plasmin inhibitor alpha(2)-antiplasmin (alpha(2)-AP) int

9 d human dermal fibroblasts plus the specific plasmin inhibitor alpha(2)-antiplasmin or dermal fibrobl

10 d into the vitreous humor with KA, whereas a plasmin inhibitor, alpha-2-antiplasmin, failed to attenu

11 thin the fibrinolytic pathway, including the plasmin inhibitor alpha2-antiplasmin (A2AP).

12 plasminogen to plasmin and inactivating the plasmin inhibitor alpha2-antiplasmin (alpha2-AP).

13 was fused to a sequence derived from alpha2-plasmin inhibitor (alpha2-PI1-8) that is a substrate for

14 The activities for plasmin of the plasmin inhibitor and bovine pancreatic trypsin inhibito

15 applicability was demonstrated by screening plasmin inhibitors and fibrinolytic bioactives from mixt

16 Neuritogenesis is also impaired by alpha(2)-plasmin inhibitor, antibodies directed against t-PA and

17 omoting these changes, as treatment with the plasmin inhibitor aprotinin had no effect.

18 ardiocytes with anti-uPAR or anti-uPA Abs or plasmin inhibitor aprotinin prior to coculturing with he

19 ith GAS were simultaneously treated with the plasmin inhibitor aprotinin, a significant reduction in

20 e of the thrombin inhibitor, hirudin, or the plasmin inhibitor, aprotinin, consistent with the interp

21 on of latent TGF-beta by TSP, but not by the plasmin inhibitor, aprotinin.

22 Furthermore, several allosteric plasmin inhibitors based on heparin mimetics have been d

23 New macrocyclic plasmin inhibitors based on our previously optimized P2-

24 ed by either tPA-deficiency or infusion of a plasmin inhibitor, both of which also block neuronal deg

25 Although plasmin inhibitors could be used in multiple disorders,

26 Inhibition of fibrinolysis by the indirect plasmin inhibitor epsilon-aminocaproic acid or by alpha2

27 nd by microsomes was inhibited by bdellin, a plasmin inhibitor from the medicinal leech Hirudo medici

28 e macrophage surface is protected from serum plasmin inhibitors, interaction of AgLDL with macrophage

29 a2-antiplasmin (alpha2AP, also called alpha2-plasmin inhibitor) is the main physiological inhibitor o

30 antiplasmin (alpha2AP), also known as alpha2-plasmin inhibitor, is the major inhibitor of the proteol

31 thus, it represents the first proteinaceous plasmin inhibitor of prokaryotic origin described to dat

32 iplasmin (alpha(2)AP), a major physiological plasmin inhibitor, or anti-annexin II IgG, blocked EMT b

33 asminogen participates in neuritogenesis, as plasmin inhibitors reduced both neurite outgrowth and ne

34 vage pathway in the setting of urokinase and plasmin inhibitors to promote clearance of the provision

35 Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology,

36 ategy for the design of potent and selective plasmin inhibitors was developed.

37 Three pairs of plasmin inhibitors were synthesized to compare the relat

38 of our recently described substrate-analogue plasmin inhibitors, which were cyclized between their P3

39 tor, human neutrophil elastase inhibitor and plasmin inhibitor, with 99mTc.